Doccla secures £15m Series A funding led by General Catalyst to expand virtual ward technology
General Catalyst led the Series A round to support the development of virtual ward infrastructure.
Share allotment filed at Companies House
Doccla provides virtual ward and remote patient monitoring technology for healthcare providers.
Doccla has raised £15m in a Series A funding round led by General Catalyst. The round also drew participation from KHP Ventures, Giant Ventures, and Speedinvest. The company provides remote patient monitoring solutions and virtual ward technology to healthcare providers. Doccla will direct the new capital towards developing its technology stack, integrating with additional medical devices and electronic health records, and expanding clinical capacity.
From the founder
"I’m very proud of our team in completing this successful financing round, marking a significant step in Doccla’s vision of making virtual wards a core part of modern healthcare systems. From the company’s beginnings in 2019, we have continued to grow and expand and have received contract extensions from all of our clients, proving the inherent value of Doccla to the healthcare sector. Combining new technology with a service layer and clinical capacity reduces work for the NHS. We look forward to using this new level of support to further build on our success by getting more hospitals on board and developing our technology and clinical capacity to help solve the hospital bed crisis and alleviate the immense pressures on the NHS and other healthcare systems."
Martin Ratz
Founder at Doccla
Investor perspective
"The virtualisation of hospital wards is critical in efficiently expanding health resources and enabling timely, safe transition of care into the home. Doccla has immense potential and is driving real impact by providing a much-needed lifeline for overwhelmed hospitals and improving patient outcomes through remote monitoring. The founders’ vision to drive more digitally-enabled, decentralised healthcare that combines physical and virtual pathways aligns with General Catalyst’s Health Assurance thesis. Importantly, their partnership approach with NHS Trusts echoes our core values of radical collaboration and responsible innovation — an innovation that improves society. At General Catalyst, we support companies that bring about powerful, positive change that endures, and we believe Martin, Dag, and the team will do just that."
Chris Bischoff
Managing Director, General Catalyst
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Expand into international markets
